Security key
22663K107
Crinetics Pharmaceuticals, Inc. - COMMON STOCK (CRNX)
CUSIP: 22663K107
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / COMMON STOCK
- Shares outstanding
- 105,000,216
- Total 13F shares
- 107,709,232
- Share change
- +3,151,817
- Total reported value
- $4,486,288,734
- Put/Call ratio
- 20%
- Price per share
- $41.65
- Number of holders
- 225
- Value change
- +$149,976,766
- Number of buys
- 124
- Number of sells
- 107
Report period
Q3 2025
Institutions
225
Top holders
10
CRNX full security history
Newer quarter: Q4 2025
Previous quarter: Q2 2025
Crinetics Pharmaceuticals, Inc. SEC filings
Crinetics Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 22663K107
Recent filing periods:
Top shareholders of CRNX - Crinetics Pharmaceuticals, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13D/G
13F
|
Company |
15%
|
13,957,269
|
$466,033,211 | +$144,432,819 | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
8.8%
|
9,256,132
|
$266,206,356 | — | 30 Jun 2025 | |
| BlackRock, Inc. |
13F
|
Company |
7.1%
|
7,418,715
|
$213,362,244 | — | 30 Jun 2025 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
6.1%
|
6,400,025
|
$184,064,719 | — | 30 Jun 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
5.5%
|
5,807,308
|
$167,018,179 | — | 30 Jun 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
5.3%
|
5,590,504
|
$160,784,000 | — | 30 Jun 2025 | |
| FARALLON CAPITAL MANAGEMENT LLC |
13F
|
Company |
4.4%
|
4,646,098
|
$133,621,778 | — | 30 Jun 2025 | |
| EcoR1 Capital, LLC |
13F
|
Company |
4.1%
|
4,288,120
|
$123,326,331 | — | 30 Jun 2025 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
3.2%
|
3,410,320
|
$98,063,217 | — | 30 Jun 2025 | |
| STATE STREET CORP |
13F
|
Company |
3.1%
|
3,224,306
|
$92,731,041 | — | 30 Jun 2025 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
2.2%
|
2,343,553
|
$67,400,584 | — | 30 Jun 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.1%
|
2,213,325
|
$63,662,462 | — | 30 Jun 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
1.9%
|
1,998,161
|
$57,467,104 | — | 30 Jun 2025 | |
| JENNISON ASSOCIATES LLC |
13F
|
Company |
1.9%
|
1,987,118
|
$57,149,516 | — | 30 Jun 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
1.6%
|
1,688,611
|
$48,564,452 | — | 30 Jun 2025 | |
| Novo Holdings A/S |
13F
|
Company |
1.5%
|
1,550,000
|
$44,578,000 | — | 30 Jun 2025 | |
| Vestal Point Capital, LP |
13F
|
Company |
1.4%
|
1,500,000
|
$43,140,000 | — | 30 Jun 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
1.1%
|
1,200,477
|
$34,525,719 | — | 30 Jun 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
1.1%
|
1,149,000
|
$33,045,240 | — | 30 Jun 2025 | |
| GW&K Investment Management, LLC |
13F
|
Company |
0.92%
|
970,810
|
$27,920,000 | — | 30 Jun 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.86%
|
900,887
|
$25,909,510 | — | 30 Jun 2025 | |
| Hood River Capital Management LLC |
13F
|
Company |
0.85%
|
888,470
|
$25,552,397 | — | 30 Jun 2025 | |
| First Light Asset Management, LLC |
13F
|
Company |
0.82%
|
864,136
|
$24,852,551 | — | 30 Jun 2025 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.81%
|
848,638
|
$24,406,872 | — | 30 Jun 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.75%
|
784,213
|
$22,553,966 | — | 30 Jun 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.73%
|
766,228
|
$22,036,717 | — | 30 Jun 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.72%
|
760,022
|
$21,858,238 | — | 30 Jun 2025 | |
| Fisher Asset Management, LLC |
13F
|
Company |
0.7%
|
737,084
|
$21,198,534 | — | 30 Jun 2025 | |
| T. Rowe Price Investment Management, Inc. |
13F
|
Company |
0.68%
|
716,172
|
$20,598,000 | — | 30 Jun 2025 | |
| BNP Paribas Asset Management Holding S.A. |
13F
|
Company |
0.68%
|
712,719
|
$20,498,000 | — | 30 Jun 2025 | |
| S.c.a. Candriam |
13F
|
Individual |
0.66%
|
693,869
|
$19,956,522 | — | 30 Jun 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.62%
|
653,635
|
$18,798,543 | — | 30 Jun 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
0.62%
|
649,138
|
$18,669,209 | — | 30 Jun 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.55%
|
573,282
|
$16,487,594 | — | 30 Jun 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.5%
|
524,951
|
$15,097,591 | — | 30 Jun 2025 | |
| RTW INVESTMENTS, LP |
13F
|
Company |
0.44%
|
467,000
|
$13,430,920 | — | 30 Jun 2025 | |
| Fiera Capital Corp |
13F
|
Company |
0.42%
|
444,330
|
$12,778,931 | — | 30 Jun 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.41%
|
433,431
|
$12,465,476 | — | 30 Jun 2025 | |
| MPM BioImpact LLC |
13F
|
Company |
0.41%
|
428,975
|
$12,337,321 | — | 30 Jun 2025 | |
| Cormorant Asset Management, LP |
13F
|
Company |
0.38%
|
400,000
|
$11,504,000 | — | 30 Jun 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.34%
|
357,677
|
$10,286,791 | — | 30 Jun 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.33%
|
345,928
|
$9,948,901 | — | 30 Jun 2025 | |
| Universal- Beteiligungs- und Servicegesellschaft mbH |
13F
|
Individual |
0.33%
|
341,705
|
$9,827,436 | — | 30 Jun 2025 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
0.32%
|
334,796
|
$9,628,732 | — | 30 Jun 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.32%
|
331,957
|
$9,547,083 | — | 30 Jun 2025 | |
| UBS Group AG |
13F
|
Company |
0.31%
|
320,545
|
$9,218,874 | — | 30 Jun 2025 | |
| Ensign Peak Advisors, Inc |
13F
|
Company |
0.3%
|
315,564
|
$9,075,621 | — | 30 Jun 2025 | |
| Prosight Management, LP |
13F
|
Company |
0.28%
|
298,123
|
$8,574,017 | — | 30 Jun 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.28%
|
292,047
|
$8,399,273 | — | 30 Jun 2025 | |
| M&G Plc |
13F
|
Company |
0.27%
|
281,896
|
$8,174,984 | — | 30 Jun 2025 |
Institutional Holders of Crinetics Pharmaceuticals, Inc. - COMMON STOCK (CRNX) as of Q3 2025
As of 30 Sep 2025,
Crinetics Pharmaceuticals, Inc. - COMMON STOCK (CRNX) was held by
225 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
107,709,232 shares.
The largest 10 holders included
FMR LLC, VANGUARD GROUP INC, WELLINGTON MANAGEMENT GROUP LLP, BlackRock, Inc., Driehaus Capital Management LLC, FARALLON CAPITAL MANAGEMENT LLC, PRICE T ROWE ASSOCIATES INC /MD/, EcoR1 Capital, LLC, JANUS HENDERSON GROUP PLC, and Paradigm Biocapital Advisors LP.
This page lists
225
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
220
Q3 2025 holders
225
Holder diff
5
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.